Cardiovascular and Renal Drugs Advisory Committee
Meeting on September 8, 2011, from 8 a.m. to 5 p.m.
Agenda: On September 8, 2011, the committee will discuss new drug application (NDA) 202439, rivaroxaban tablets, submitted by Johnson & Johnson Pharmaceutical Research and Development, L.L.C., on behalf of Ortho- McNeil-Janssen-Pharmaceuticals, for the prevention of stroke and systemic embolism (blood clots other than in the head) in patients with nonvalvular atrial fibrillation (abnormally rapid contractions of the atria, the upper chambers of the heart).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment